Clinical and Angiographic Outcomes of
Drug-Eluting Stents in Patients With Large
Vessel and Single Coronary Artery Lesion
- Affiliated Author(s)
- 조윤경; 김형섭; 남창욱; 허승호; 김권배
- Alternative Author(s)
- Cho, Yun Kyeong; Kim, Hyung Seop; Nam, Chang Wook; Hur, Seung Ho; Kim, Kwon Bae
- Journal Title
- Clinical Cardiology
- Issued Date
The aim of this study was to evaluate and compare the clinical and angiographic outcomes of 3 drug-eluting stents (DES) in patients with large vessel diameter and single coronary artery lesions.
The efficacy of 3 DESs may be similar.
A total of 411 consecutive patients who visited 3 university hospitals from June 2004 to December 2007 and had a single coronary lesion which was treated with the use of a DES that was 3.5 mm in diameter were enrolled in this study. Patients were divided into 3 stent groups: Paclitaxel-eluting stent (PES, n = 105), Sirolimus-eluting stent (SES, n = 259), and Zotarolimus-eluting stent (ZES, n = 47). The study end point was a composite of major adverse cardiac events (MACE) including cardiac death, myocardial infarction (MI), and ischemia-driven target-vessel revascularization (TVR) for 12 months.
Baseline characteristics were not different. Late loss was higher in the ZES group than the other stents (0.5 ± 0.4 mm in SES vs 0.3 ± 0.5 mm in PES, 0.7 ± 0.5 mm in ZES, P = 0.001). The total MACE-free survival rate was not significantly different between the SES group and the PES group (98.8% in SES vs 97.1% in PES, P = 0.252) or the PES group and the ZES group (97.1% in PES vs 93.6% in ZES, P = 0.301). However, the SES group showed a significantly better MACE-free survival rate compared with the ZES group (98.8% in SES vs 93.6% in ZES, P = 0.018).
Clinical and angiographic outcomes of DES in a large vessel diameter and single coronary artery is excellent and SES appears to show better angiographic and clinical outcomes than ZES. Copyright © 2010 Wiley Periodicals, Inc.
- Authorize & License
- Files in This Item:
Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.